Paclitaxel, Cisplatin and Methotrexate Combination Chemotherapy is Active in the Treatment of Refractory Urothelial Malignancies
- 1 November 1995
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 154 (5) , 1719-1722
- https://doi.org/10.1016/s0022-5347(01)66765-x
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitroBritish Journal of Cancer, 1994
- Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristineZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- Letters to the editor: Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancerAnnals of Oncology, 1993
- A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of Clinical Oncology, 1992
- Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumorsCancer, 1991
- Treatment of Advanced Transitional Cell Carcinoma of the Bladder With Continuous-Infusion Gallium NitrateJNCI Journal of the National Cancer Institute, 1991
- Sequences of taxol and cisplatin: a phase I and pharmacologic study.Journal of Clinical Oncology, 1991
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1988
- Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.Journal of Clinical Oncology, 1985